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Knowledge on the effects of gabapentin (GBP) in learning disabled patients is limited. The objective of this study was to
assess antiepileptic efficacy and tolerability of GBP in routine therapy. A retrospective open observational study design was
applied. Twenty-nine consecutive residential patients with simple and/or complex partial seizures with or without secondary
generalization and with different degrees of learning disability were included. All patients had severe therapy-resistant epilepsy.
GBP was administered as add-on therapy. Dosages were progressively increased up to 1600–2400 mg/day (in a number of cases
up to 4800 mg/day), in accordance with clinical requirements. The seizure frequency was recorded and compared between a
baseline and a treatment period (after 3 months of titration) of 3 months duration each.
Only three patients (10.3%) had a reduction of their seizure frequency by 50% or more. No patient became seizure-free.
Unwanted side effects, mostly mild and dose-dependent, occurred in 37.9% of all patients. Somnolence and ataxia were the
most frequently observed unwanted effects. In two cases hyperphagia/weight increase, and in two other cases edema occurred.
We conclude the efficacy of GBP in learning disabled patients with highly therapy-resistant partial seizures is limited.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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Dear Sir,
The few reports on the use of gabapentin (GBP) in the
antiepileptic treatment of learning-disabled patients
are very positive, indicating responder rates from 34
to 56%1–3. We do not want to miss to communicate
that our own experience of a large institution special-
izing in long-term treatment of chronic epilepsy in the
learning disabled is much more disappointing.
As any new antiepileptic drug is hopeful for
therapy-resistant patients, GBP started to be used in
Bethel after its introduction to the market.
The objective of this study was to assess efficacy
and tolerability of the new drug in routine therapy.
To avoid the ethical and legal difficulties of con-
trolled studies conducted in handicapped patients, the
method of an open observational study in accordance
with the guidelines published by Linden4 was chosen.
Twenty-nine consecutive adult patients with simple
and/or complex partial seizures with or without sec-
ondary generalization who were treated with GBP be-
tween 1996 and 1998 were included. All patients were
in long-term residential care in the Bethel Epilepsy
Centre (mean duration of residential care: 18.8 years)
because of their severe epilepsy (mean duration of
epilepsy: 32.4 years) and additional impairments.
The physicians of the Bethel medical service
(mostly neurologists, one pediatrician, all with special
experience in the diagnosis and treatment of epilepsy)
selected the patients on clinical grounds, preferably
patients with frequent and/or disabling seizures. Re-
sistance against at least one traditional AED was
precondition, but in fact nearly all study participants
were resistant against several traditional AEDs up
to maximum tolerable dosages and in several cases
against one or two new AED (mostly LTG).
Diagnoses of epilepsy and seizure types were based
on the seizure descriptions and EEG findings found in
the patients’ case histories.
All patients or their legal representatives had given
consent in GBP treatment.
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Table 1: Side effects.
Somnolence 4 13.8%
Dizziness/ataxia 3 10.3%
Edema 2 6.9%
Hyperphagia/weight increase 2 6.9%
Diplopia 1 3.4%
Nystagmus 1 3.4%
Sedation with dysphasia and forgetfulness 1 3.4%
In a number of patients more than one side effect occurred.
According to the character of the study, there was
no fixed titration scheme. Usually, GBP treatment
was started on low dosages (e.g. 300–400 mg/day),
followed by progressive dosage increases up to
1600–2400 mg/day, in accordance with clinical re-
quirements. In a number of cases, the GBP dosage
was further increased up to a maximum daily dose
of 4800 mg. The aim was to obtain the best possible
antiepileptic effects. Concomitant medication could
be adjusted, when clinically appropriate.
Data with respect to seizure frequency and treat-
ment details were retrospectively extracted from the
continual records of seizures kept on all resident
patients. Most of the seizure documentation and clas-
sification was done by trained and experienced staff.
This ensured that the documentation was as complete
as possible.
The seizure frequency was compared between a
baseline and a treatment period (after 3 months of
titration) of 3 months duration each.
RESULTS
Eleven patients had mild, 9 had moderate, 2 had se-
vere (1: undetermined) learning disability. Six patients
had borderline intelligence or only neuropsycholog-
ical deficits like psychomotor slowing or memory
disturbance.
The comedication, most frequently carbamazepine
or valproate, remained widely stable throughout the
trial.
Only three patients (10.3%) had a reduction of their
seizure frequency by 50% or more (responders). No
patient became completely seizure-free. The three re-
sponders had a wide variety of GBP daily doses (900–
3200 mg/day) and serum concentrations (0.38–4.32
µg/ml).
Eleven patients (37.9%) experienced unwanted side
effects (Table 1). The spectrum of side effects corre-
sponded well to the literature, somnolence and ataxia
being the most frequently observed unwanted effects.
They were dose-dependent, mostly mild, and disap-
peared after dose reduction. In two cases, we saw
hyperphagia with weight increase, and in two other
cases edema. (In one additional case which was not
included in the study because she had generalised
seizures, a dose as low as 400 mg/day caused severe
somnolence. Intolerance against small doses of AED
is a phenomenon not so unusual in the treatment of
severely handicapped patients.)
The responder rate of only 10.3% found in our study
is much lower than reported in the literature. This dis-
crepancy is most probably due to differences in pa-
tient selection, the Bethel residential patients probably
being one of the most highly therapy-resistant patient
groups.
We have earlier reported on similar studies with lam-
otrigine (LTG) and topiramate (TPM) in the same pop-
ulation (although not necessarily in the same patients)
with considerably higher responder rates of 28.8% 5
(LTG), respectively, 37.5% 6 (TPM). In a further study
with levetiracetam, the responder rate was 41.3% (un-
published data). Marson7, in an attempt to compare six
new AED, calculated the odds ratios as a measure of
efficacy. Although all confidence intervals were over-
lapping, it was interesting to note the GBP odds ratio
was lower than those of LTG, tiagabine, TPM, viga-
batrin, and zonisamide.
We conclude GBP, although well tolerated in most
cases, is not the treatment of choice in learning-
disabled patients with highly therapy-resistant partial
seizures because its efficacy in this difficult-to-manage
patient group is limited.
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